FLGT News and Press, Fulgent Genetics Inc. From 02/14/23

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that it w...

Summary Aswath Damodaran is an investing and finance authority on markets & valuation, among many other things. In a 2022 interview, he provided a masterclass in inflation, some lessons in history, and potential ways to protect your portfolio this time around. In a previous piec...

San Diego, California--(Newsfile Corp. - January 24, 2023) -  The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Fulgent Genetics, Inc. (NASDAQ: FLGT) shares. Investors who purchased Fulgent Genetics, Inc. (NASDAQ: FLGT) shares prior to 2021 and c...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Reggie Groves to its board of directors, effective January 3, 2023. “Reggie possesses a diverse business skill set and a glob...

PHILADELPHIA, Dec. 27, 2022 (GLOBE NEWSWIRE) --  Barrack, Rodos & Bacine (BR&B) is investigating Fulgent Genetics Inc. based on issues arising from its recent acquisitions, including the acquisition of Fulgent Pharma LLC, a wholly owned subsidiary of Fulgent Pharma Holdings, which it...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors who avoided losing money this year are positioned to consider stocks that are strong conviction buys. An investment idea earns that level of faith when management demonstrates a consistent history of leadership. For...

Summary What started as a seemingly innocuous leadership transition at one of the country's leading molecular diagnostic firms, NeoGenomics, Inc., has evolved into something much more chaotic. After the departure of former NeoGenomics, Inc. CEO and company veteran Douglas VanOort last y...

Summary As the COVID testing frenzy winds down, FLGT is faced with a pleasant problem: what to do with the money it has amassed during the pandemic. Its $880 million dry powder represents a major war chest that can be used to fund acquisitions to fund future growth free of leverage or s...

SAN DIEGO, CA / ACCESSWIRE / December 5, 2022 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Fulgent Genetics, Inc. (NASDAQ: FLGT) shares. Investors who purchased Fulgent Genetics, Inc. (NASDAQ:FLGT) shares in November 2019 or earlier and contin...

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Fulgent Genetics, Inc. (NASDAQ: FLGT). Investors who purchased Fulgent Genetics, Inc. (NASDAQ: FLGT) shares long-term and continue to hold any ...